Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)

What changed: Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)

Cancer page →

Every dated change on the records linked to Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval8Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordCutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)
Facts on this page last checked
When this page itself was last checked or edited.

2018 · 2

2017 · 1

2017MilestoneBrentuximab vedotin
ALCANZA: brentuximab vedotin beats standard therapy in CD30-positive disease
A milestone in how this cancer is treated.

2012 · 1

2012ApprovalMogamulizumab
Mogamulizumab approved in JP
Relapsed CCR4+ adult T-cell leukaemia/lymphoma; later PTCL/CTCL

2009 · 1

2009ApprovalRomidepsin
Romidepsin approved in US
Cutaneous T-cell lymphoma after ≥1 systemic therapy

2006 · 2

2001 · 1

2001ApprovalBexarotene
Bexarotene approved in EU
Skin manifestations of advanced-stage CTCL refractory to at least one systemic treatment

1999 · 3

1987 · 1

1987MilestoneMethoxsalen (extracorporeal photopheresis)
Extracorporeal photopheresis approved for cutaneous T-cell lymphoma
A milestone in how this cancer is treated.

1953 · 1

1953ApprovalMethotrexate
Methotrexate approved in US
ALL, choriocarcinoma, and later osteosarcoma, breast, head and neck, lung, lymphoma, mycosis fungoides

1806 · 1

1806MilestoneCutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)
Alibert describes mycosis fungoides
A milestone in how this cancer is treated.